Skip to main content
SpringerLink
Log in

Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

We have recently shown that either exogenous or endogenous, transfected OPN induces both uPA expression and increased invasiveness of 21PT (non-tumorigenic) and 21NT (tumorigenic) human mammary epithelial cells. Here we asked whether uPA contributes functionally to the increased invasiveness of these cells. The most invasive OPN-transfected cells were assessed for migration through Matrigel in transwell assays, in the presence or absence of various blocking antibodies and uPA inhibitors. Antibodies to both uPA and uPA receptor (uPAR) were shown to significantly inhibit cell invasion, as did the uPA inhibitors (plasminogen activator inhibitor-1 [PAI-1], p-aminobenzamidine [PABN], aprotinin, and amiloride). Both anti-uPA and anti-uPAR antibodies inhibited invasion to a level comparable to that of the control vector transfected cells. In contrast, non-specific IgG showed no anti-invasive effect. Cell migration experiments performed with the parental cell lines in the presence or absence of anti-uPA or anti-uPAR antibodies showed that uPA is also required for migratory responsiveness to exogenous OPN. These data thus provide direct evidence that OPN-induced invasion and migration of these cells requires uPA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tuck AB, O'Malley FP, Singal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig G, Chambers AF: Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 79: 502-508, 1998

    Google Scholar 

  2. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF: Elevated plasma osteopontin inmetastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3: 605-611, 1997

    Google Scholar 

  3. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF: Osteopont in induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18: 4237-4246, 1999

    Google Scholar 

  4. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47: 1039-1047, 1995

    Google Scholar 

  5. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16: 2319-2332, 1997

    Google Scholar 

  6. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442, 1997

    Google Scholar 

  7. Andreasen P-A, Kjøller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997

    Google Scholar 

  8. Yebra M, Parry GCN, Strömblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA: Requirement of receptorbound urokinase-type plasminogen activator for integr in ?v? 5-directed cell migration. J Biol Chem 271: 29393-29399, 1996

    Google Scholar 

  9. Carriero MV, Vecchio SD, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP: Urokinase receptor interacts with ?v?5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 59: 5307-5314, 1999

    Google Scholar 

  10. Band V, Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, Connolly J, Sager R: Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res 50: 7351-7357, 1990

    Google Scholar 

  11. Tuck AB, Wilson SM, Chambers AF: Ras transfection and expression does not induce progression from tumorigenicity to metastatic ability in mouse LTA cells. Clin Exp Metast 8: 417-431, 1990

    Google Scholar 

  12. Tuck AB, Wilson SM, Khokha R, Chambers AF: Different patterns of gene expression in ras-resistant and ras-sensitive cells. J Natl Cancer Inst 83: 485-491, 1991

    Google Scholar 

  13. Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW, Fisher LW: cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7: 491-502, 1990

    Google Scholar 

  14. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F: The human urokinase-plasminogen activator gene and its promoter. Nucl Acids Res 13: 2759-2771, 1985

    Google Scholar 

  15. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474, 1990

    Google Scholar 

  16. Simon C Juarez J, Nicolson GL, Boyd D: Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase, on urokinase expression and in vitro invasion. Cancer Res 56: 5369-5374, 1996

    Google Scholar 

  17. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF: Site-directed mutagenesis of the arginineglycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 57: 680-690, 1995

    Google Scholar 

  18. Xuan JW, Hota C, Chambers AF: Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 54: 247-255, 1994

    Google Scholar 

  19. Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PF: Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases-a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 61: 1-12, 2000

    Google Scholar 

  20. Senger DR, Perruzzi CA: Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1314: 13-24, 1996

    Google Scholar 

  21. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF: Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78: 465-475, 2000

    Google Scholar 

  22. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J: Intracellular osteopont in is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184: 118-130, 2000

    Google Scholar 

  23. Sung V, Gilles C, Murray A, Clarke R, Aaron AD, Azumi N, Thompson EW: The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp Cell Res 241: 273-284, 1998

    Google Scholar 

  24. Oates AJ, Barraclough R, Rudland PS: The identification of osteopont in as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13: 97-104, 1996

    Google Scholar 

  25. Chen H, Ke Y, Oates AJ, Barraclough R, Rudland PS: Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14: 1581-1588, 1997

    Google Scholar 

  26. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW: A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta5. J Biol Chem 270: 26232-26238, 1995

    Google Scholar 

  27. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM: The adhesive and migratory effects of osteopont in are mediated via distinct cell surface integrins. role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95: 713-724, 1995

    Google Scholar 

  28. Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R, Giachelli CM: Osteopont in N-terminal domain contains a cryptic adhesive sequence recognized by alpha9 beta1 integrin. J Biol Chem 271: 28485-28491, 1996

    Google Scholar 

  29. Denda S, Reichardt LF, Muller U: Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Mol Biol Cell 9: 1425-1435, 1998

    Google Scholar 

  30. Bayless KJ, Meininger GA, Scholtz JM, Davis GE: Osteopontin is a ligand for the alpha4 beta1 integrin. J Cell Sci 111: 1165-1174, 1998

    Google Scholar 

  31. Weber GF, Ashkar S, Glimcher MJ, Cantor H: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271: 509-512, 1996

    Google Scholar 

  32. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, Cardiff RD: CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 176: 206-215, 1998

    Google Scholar 

  33. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T: CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59: 219-226, 1999

    Google Scholar 

  34. Jeffers M, Rong S, Vande Woude GF: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16: 1115-1125, 1996

    Google Scholar 

  35. Pepper MS, Matsumoto K, Nakamura T, Orci L, Montesano R: Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 267: 20493-20496, 1992

    Google Scholar 

  36. Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E: Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem 274: 16377-16386, 1999

    Google Scholar 

  37. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM: Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 11: 4825-4833, 1992

    Google Scholar 

  38. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF: The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60: 342-349, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology, University of Western Ontario, Ontario, Canada

    Alan B. Tuck, Charulata Hota & Ann F. Chambers

  2. Departments of Oncology, University of Western Ontario, Ontario, Canada

    Alan B. Tuck, Charulata Hota & Ann F. Chambers

  3. London Health Sciences Centre, London, Ontario, Canada

    Alan B. Tuck & Charulata Hota

  4. London Regional Cancer Centre, London, Ontario, Canada

    Alan B. Tuck, Charulata Hota & Ann F. Chambers

Authors
  1. Alan B. Tuck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charulata Hota
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ann F. Chambers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tuck, A.B., Hota, C. & Chambers, A.F. Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 70, 197–204 (2001). https://doi.org/10.1023/A:1013095329825

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013095329825

Search

Navigation